Enrollment Continuing in REFINE-ALS Biomarker Study for Radicava

Enrollment Continuing in REFINE-ALS Biomarker Study for Radicava

314279

Enrollment Continuing in REFINE-ALS Biomarker Study for Radicava

Thanks to the implementation of proactive safety measures for the COVID-19 pandemic, Mitsubishi Tanabe Pharma America (MTPA) has enrolled at least 33 adults with amyotrophic lateral sclerosis (ALS) in its ongoing REFINE-ALS biomarker study. “ALS patient needs remain MTPA’s primary focus, so it was a priority to address the evolving concerns of the ALS community during the pandemic and offer appropriate alternatives for patients to participate in the REFINE-ALS study through a virtual setting,” Atsushi Fujimoto,…

You must be logged in to read/download the full post.